IMMUNOTECHOLOGIES CORE

免疫技术核心

• 批准号: 7764477
• 负责人: SCOTT E PLEVY
• 金额: $ 13.82万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-15 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7764477
• 关键词: Animal Model; Autoimmune Process; Biological Assay; Biological Markers; Biology; Cells; Client; Clinical; Clinical Trials; Collaborations; Communities; Consultations; Core Facility; Custom; Cyclic Nucleotides; Development; Disease; Eicosanoids; Enteral; Enzyme-Linked Immunosorbent Assay; Epithelial; Equipment; Funding; Gastrointestinal Diseases; Goals; Growth Factor; Human; Human Resources; Immune; Immune response; Immune system; Immunoassay; Immunocompetence; Immunologic Monitoring; Immunologics; Immunosuppression; Immunosuppressive Agents; Immunotherapeutic agent; Industry; Inflammation; Inflammatory; Inflammatory Bowel Diseases; Intervention; Irritable Bowel Syndrome; Laboratories; Liver diseases; Malignant Neoplasms; Measurement; Measures; Mediation; Mesenchymal; Methods; Monitor; Mus; Neoplasms; Organ; Patients; Pharmacotherapy; Phosphoproteins; Play; Price; Procedures; Protein Analysis; Proteomics; Quality Control; Radioimmunoassay; Research; Research Design; Research Personnel; Role; Safety; Serum; Services; Signaling Molecule; Site; System; Techniques; Technology; Therapeutic Intervention; Time; Tissue Extracts; Tissues; Training; Translational Research; Transplantation; United States National Institutes of Health; Vaccination; Vaccines; Validation; assay development; base; cancer immunotherapy; clinical efficacy; cost; cost effective; cytokine; discount; experience; gastrointestinal; immunogenicity; interest; member; new technology; novel; peptide hormone; prospective; reconstitution; repaired; serological marker; symposium; technology development

When the UNC Center for Gastrointestinal Biology and Disease was initially established it emphasized analysis of epithelial transport, grovrth, development, and repair, including control of these functions by subepithelial immune and mesenchymal cells. From the outset, it was recognized that a Core Facility capable of measuring levels of soluble signaling molecules (such as peptide hormones, growth factors, eicosanoids, cytokines, and cyclic nucleotides) would be essential to investigators pursuing these goals. For this reason, an Immunoassay (IA) Core was established, and staffed with a Core Director (Dr. Don Powell) and a Core Technician. In 1991, Dr. Michael Goy replaced Dr. Powell as the IA Core Director. Due to steadily increasing demand for Core services, an additional half-time technician was hired in 2002. In January 2008, Scott Plevy replaced Michael Goy as IT Core Director. The strategic reason for this change was Dr. Plevy's expertise in cytokine biology and quantitative technologies, which historically has comprised the predominant usage of the core. In addition. Dr. Plevy brought new expertise in biomarker development and immune monitoring, which as described, will become new initiatives of the Core based on the prospective needs of CGIBD members. In April 2008, Carlton Anderson became the new IT Core Technician and Assistant Director. Mr. Anderson provides a wealth of laboratory experience and expertise. He has rapidly assimilated techniques for the most commonly requested ELISAs, has been trained on all existing equipment, and has developed, under the guidance of Dr. Plevy, new cost effective technologies for the Core. In parallel with these personnel changes, the objectives ofthe IT Core have also evolved and expanded. As the focus ofthe Center has shifted from diarrheal to inflammatory diseases and cancer, the needs of Center members have shifted and the IT Core has acquired new capabilities. From an initial repertoire of three immunoassays performed for a few investigators, the Core now serves a client base of over 50 laboratories, and offers a sophisticated array of services, including (a) over 50 diffierent types of ELISA and RIA measurements, (b) custom immunoassay development, and (c) quantitative multiplex proteomic analysis that can be adapted to numerous applications. During the last funding cycle, as described elsewhere in this application, the proteomic component ofthe IT Core was eliminated. This decision reflects the existence of multiple cores on campus that provide cost-eff^ective proteomic analysis, and followed polling and approval of CGIBD executive committee who concluded that such technology is no longer a high priority. To provide expanded and significantly more cost-effective services to the CGIBD community. Dr. Plevy initiated new cytokine ELISA development for the most requested cytokine assays based on established technology in CGIBD investigator's laboratories. Mr. Anderson has already negotiated better prices for standard ELISA kits; therefore, CGIBD investigators immediately benefitted by a 10- 35% reduction in costs for services provided. With increased emphasis on translational research, the IT Core has embarked upon several new initiatives. An emphasis of the IT Core moving forward, facilitated by the acquisition of new technology platforms and thematically consistent vnth the NIH Roadmap, will be biomarker development vnth an emphasis on human studies. We are now performing multiplex protein analysis using xMAP technology. We have negotiated vnth Bio-Rad and R and D Systems toreceive discounted prices on multiplex kits for the Core's Bio-Plex 200 system which vnll facilitate human and murine research, and contribute to biomarker development. Additionally, we are planning an on-site symposium to better acquaint investigators with the multiplex platform. We have also established collaboration with Glycominds, Inc. to develop ELISA-based serological markers directed against the enteric microbiota in human inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and inflammatory liver diseases. Finally, as a result of recent NIH funded and industry sponsored activities of several Center investigators, the Core has taken an interest in immune monitoring in IBD patients, including but not limited to, immunogenicity and vaccine monitoring, and immunocompetence and reconstitution during therapeutic interventions. Development of this technology will be applicable across many GI disorders where assessing subtle effects on the human immune system vnll be critical to understand safety and efficacy of clinical interventions, including trials of vaccinations, cellular therapy, drug therapy, cancer immunotherapy, transplantation, and autoimmune/inflammatory disorders.

北卡罗来纳大学胃肠道生物学和疾病中心最初成立时， 重点分析上皮的运输、生长、发育和修复，包括控制 这些功能是通过上皮下免疫细胞和间充质细胞实现的。从一开始，它就被公认为 能够测量可溶信号分子(如多肽)水平的核心设备 激素、生长因子、二十烷类化合物、细胞因子和环核苷酸)将是 追求这些目标的调查人员。为此，建立了免疫分析(IA)核心，并 配备一名核心董事(唐·鲍威尔博士)和一名核心技术人员。1991年，迈克尔·戈伊博士 取代鲍威尔博士成为内务部核心主任。由于对核心服务的需求稳步增长， 2002年雇用了额外的半职技术员。 2008年1月，Scott Plevy取代Michael Goy成为IT核心总监。战略原因 这一变化是普列维博士在细胞因子生物学和定量技术方面的专业知识， 在历史上一直是核心的主要用法。此外。普列维博士带来了新的 如上所述，生物标记物开发和免疫监测方面的专业知识将成为新的 核心倡议基于CGIBD成员的预期需求。2008年4月，卡尔顿 安德森成为新的IT核心技术员和助理总监。安德森先生提供了一个 丰富的实验室经验和专业知识。他已经迅速吸收了大部分的技巧 共同要求的ELISA，接受了关于所有现有设备的培训，并在 在Plevy博士的指导下，为Core提供了具有成本效益的新技术。 在这些人事变动的同时，信息技术核心的目标也发生了变化， 扩大了。随着该中心的重点从腹泻转向炎症性疾病和癌症， 中心成员的需求发生了变化，IT核心获得了新的功能。从一个 最初为一些研究人员进行了三项免疫分析，核心现在提供 拥有超过50个实验室的客户群，并提供一系列复杂的服务，包括：(A)超过50个 不同类型的ELISA和RIA测量，(B)定制免疫分析的发展，和(C) 可适用于多种应用的定量多重蛋白质组分析。在.期间 上一个资金周期，如本申请中其他部分所述，IT的蛋白质组组件 核心被淘汰了。这一决定反映了园区中存在多个核心，这些核心提供 成本效益蛋白质组分析，并遵循CGIBD执行委员会的投票和批准 世卫组织的结论是，这种技术不再是高度优先的。 向CGIBD社区提供扩展且显著更具成本效益的服务。 Plevy博士发起了新的细胞因子ELISA开发，用于最受欢迎的细胞因子分析，其基础是 CGIBD调查员实验室中的成熟技术。安德森先生已经进行了谈判 更优惠的价格；因此，CGIBD调查人员立即受益于10- 提供的服务成本降低35%。 随着对翻译研究的日益重视，IT核心开始了几项 新举措。IT核心向前发展的重点，通过收购新的 技术平台和主题一致的vnth NIH路线图将成为生物标志 发展强调人文科学。我们现在正在进行多重蛋白质 使用xMAP技术进行分析。我们已经就vnth Bio-Rad和研发系统进行了谈判，以获得 核心的Bio-Plex 200系统的多路复用器套件的折扣价格，这将为人类 和小鼠研究，并为生物标记物的开发做出贡献。此外，我们正在计划一项 现场座谈会，让调查人员更好地了解多元化平台。我们还有 与Glycominds，Inc.建立合作，开发基于ELISA的血清学标记 针对人类炎症性肠病(IBD)、肠易激中的肠道微生物区系 综合征(IBS)和炎症性肝病。最后，由于最近美国国立卫生研究院资助和 行业赞助的几个中心调查人员的活动，核心对 IBD患者的免疫监测，包括但不限于免疫原性和疫苗 治疗干预期间的监测、免疫活性和重建。 这项技术的开发将适用于许多胃肠道疾病，在这些疾病中，评估微妙 对人体免疫系统的影响将是了解临床安全性和有效性的关键。 干预措施，包括疫苗接种试验、细胞疗法、药物疗法、癌症免疫疗法、 移植和自身免疫性/炎症性疾病。